TITLE

The S40 residue in HIV-1 Gag p6 impacts local and distal budding determinants, revealing additional late domain activities

AUTHOR(S)
Watanabe, Susan M.; Min-Huei Chen; Khan, Mahfuz; Ehrlich, Lorna; Kemal, Kimdar Sherefa; Weiser, Barbara; Binshan Shi; Chaoping Chen; Powell, Michael; Anastos, Kathryn; Burger, Harold; Carter, Carol A.
PUB. DATE
December 2013
SOURCE
Retrovirology;2013, Vol. 10 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background HIV-1 budding is directed primarily by two motifs in Gag p6 designated as late domain-1 and -2 that recruit ESCRT machinery by binding Tsg101 and Alix, respectively, and by poorly characterized determinants in the capsid (CA) domain. Here, we report that a conserved Gag p6 residue, S40, impacts budding mediated by all of these determinants. Results Whereas budding normally results in formation of single spherical particles ~100 nm in diameter and containing a characteristic electron-dense conical core, the substitution of Phe for S40, a change that does not alter the amino acids encoded in the overlapping pol reading frame, resulted in defective CA-SP1 cleavage, formation of strings of tethered particles or filopodia-like membrane protrusions containing Gag, and diminished infectious particle formation. The S40F-mediated release defects were exacerbated when the viral-encoded protease (PR) was inactivated or when L domain-1 function was disrupted or when budding was almost completely obliterated by the disruption of both L domain-1 and -2. S40F mutation also resulted in stronger Gag-Alix interaction, as detected by yeast 2-hybrid assay. Reducing Alix binding by mutational disruption of contact residues restored single particle release, implicating the perturbed Gag-Alix interaction in the aberrant budding events. Interestingly, introduction of S40F partially rescued the negative effects on budding of CA NTD mutations EE75,76AA and P99A, which both prevent membrane curvature and therefore block budding at an early stage. Conclusions The results indicate that the S40 residue is a novel determinant of HIV-1 egress that is most likely involved in regulation of a critical assembly event required for budding in the Tsg101-, Alix-, Nedd4- and CA N-terminal domain affected pathways.
ACCESSION #
92894582

 

Related Articles

  • HIV Protease Inhibitors - The Next Generation. Turner, Steve R. // Current Medicinal Chemistry - Anti-Infective Agents;Apr2002, Vol. 1 Issue 2, p141 

    Inhibitors of HIV protease have been key components of highly active retroviral therapy, which is credited with dramatically reducing the mortality and morbidity associated with HIV infection. Nevertheless, currently available therapies are insufficiently effective in a significant proportion of...

  • Resistance to the HIV Protease Inhibitor Amprenavir In Vitro and in Clinical Studies: A Review. Tisdale, M.; Myers, R.; Randall, S.; Maguire, M.; Ait-Khaled, M.; Elston, R.; Snowden, W. // Clinical Drug Investigation;2000, Vol. 20 Issue 4, p267 

    Amprenavir (APV) is a highly active and selective HIV protease inhibitor (PI) that is used for the treatment of HIV infection in adults and children. In this review we present data from extensive resistance studies undertaken during the development of amprenavir. These include in vitro and...

  • Feature Selection Combined with Neural Network Structure Optimization for HIV-1 Protease Cleavage Site Prediction. Liu, Hui; Shi, Xiaomiao; Guo, Dongmei; Zhao, Zuowei; Yimin // BioMed Research International;4/15/2015, Vol. 2015, p1 

    It is crucial to understand the specificity of HIV-1 protease for designing HIV-1 protease inhibitors. In this paper, a new feature selection method combined with neural network structure optimization is proposed to analyze the specificity of HIV-1 protease and find the important positions in an...

  • Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals. Keiko Sakai; Takayuki Chikata; Brumme, Zabrina L.; Brumme, Chanson J.; Hiroyuki Gatanag; Shinichi Oka; iMasafumi Takiguch // Retrovirology;11/19/2015, Vol. 12, p1 

    Background: HLA class I-associated escape mutations in HIV-1 Gag can reduce viral replication, suggesting that associated fitness costs could impact HIV-1 disease progression. Previous studies in North American and African cohorts have reported reduced Gag-Protease mediated viral replication...

  • MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1. Fricke, Thomas; White, Tommy; Schulte, Bianca; de Souza Aranha Vieira, Daniel; Dharan, Adarsh; Campbell, Edward; Brandariz-Nuñez, Alberto; Diaz-Griffero, Felipe // Retrovirology;2014, Vol. 11 Issue 1, p1 

    Background The IFN-α-inducible restriction factor MxB blocks HIV-1 infection after reverse transcription but prior to integration. Genetic evidence suggested that capsid is the viral determinant for restriction by MxB. This work explores the ability of MxB to bind to the HIV-1 core, and the...

  • Antiretroviral Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Protease from Paired Cerebrospinal Fluid and Plasma Samples. Venturi, Giulietta; Catucci, Marinunzia; Romano, Laura; Corsi, Paola; Leoncini, Francesco; Valensin, Pier E.; Zazzi, Maurizio // Journal of Infectious Diseases;2/1/2000, Vol. 181 Issue 2, p740 

    Describes HIV-1 reverse transcriptase and protease sequences obtained from paired cerebrospinal fluid and plasma samples for patients under different antiretroviral regimens and patients without anti-HIV-1 therapy. Difference in the effect of antiretroviral treatment on HIV-1 replication in the...

  • Erratum to: Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.  // Retrovirology;11/30/2015, Vol. 12, p1 

    A correction to the article "Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals" by Keiko Sakai is presented.

  • Raltegravir-containing HAART regimen.  // Reactions Weekly;10/25/2008, Issue 1225, p22 

    The article presents a case study of a 59-year-old man who developed resistance to integrase inhibitors and received raltegravir, darunavir, and ritonavir for human immunodeficiency virus (HIV)-2 infection. There were found mutations related with resistance on the reverse transcriptase and...

  • Proteolytic activity of IgG antibodies from blood of acquired immunodeficiency syndrome patients. Odintsova, E. S.; Kharitonova, M. A.; Baranovskii, A. G.; Sizyakina, L. P.; Buneva, V. N.; Nevinsky, G. A. // Biochemistry (00062979);Mar2006, Vol. 71 Issue 3, p251 

    Proteolytic activity of polyclonal IgG antibodies (Abs) from the blood of AIDS patients was analyzed for the first time. These Abs were shown to display higher activity in hydrolysis of β-casein than in hydrolysis of human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) or human...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics